MA41643A - Formulations pharmaceutiques d'inhibiteur de la tyrosine kinase de bruton - Google Patents
Formulations pharmaceutiques d'inhibiteur de la tyrosine kinase de brutonInfo
- Publication number
- MA41643A MA41643A MA041643A MA41643A MA41643A MA 41643 A MA41643 A MA 41643A MA 041643 A MA041643 A MA 041643A MA 41643 A MA41643 A MA 41643A MA 41643 A MA41643 A MA 41643A
- Authority
- MA
- Morocco
- Prior art keywords
- tyrosine kinase
- kinase inhibitor
- pharmaceutical formulations
- inhibitor pharmaceutical
- bruton tyrosine
- Prior art date
Links
- 229940124291 BTK inhibitor Drugs 0.000 title 1
- 229940125814 BTK kinase inhibitor Drugs 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562127717P | 2015-03-03 | 2015-03-03 | |
| PCT/US2016/020467 WO2016141068A1 (fr) | 2015-03-03 | 2016-03-02 | Formulations pharmaceutiques d'inhibiteur de la tyrosine kinase de bruton |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA41643A true MA41643A (fr) | 2018-01-09 |
| MA41643B1 MA41643B1 (fr) | 2024-02-29 |
Family
ID=59254075
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA41643A MA41643B1 (fr) | 2015-03-03 | 2016-03-02 | Formulations pharmaceutiques d'inhibiteur de la tyrosine kinase de bruton |
Country Status (2)
| Country | Link |
|---|---|
| AR (1) | AR103832A1 (fr) |
| MA (1) | MA41643B1 (fr) |
-
2016
- 2016-03-02 AR ARP160100550A patent/AR103832A1/es unknown
- 2016-03-02 MA MA41643A patent/MA41643B1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MA41643B1 (fr) | 2024-02-29 |
| AR103832A1 (es) | 2017-06-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201907661B (en) | Pharmaceutical formulations of a bruton's tyrosine kinase inhibitor | |
| IL255831A (en) | Inhibitors of bruton's tyrosine kinase | |
| IL250085A0 (en) | New compounds of proton tyrosine kinase inhibitor | |
| EP3414234A4 (fr) | Inhibiteurs de la tyrosine kinase de bruton | |
| ZA201805439B (en) | Bruton's tyrosine kinase inhibitors | |
| MA41350A (fr) | Synthèse d'un inhibiteur de la tyrosine kinase de bruton | |
| EP3174539A4 (fr) | Inhibiteurs de la tyrosine kinase de bruton | |
| EP3141546A4 (fr) | Inhibiteur de la tyrosine kinase de bruton | |
| MA50541A (fr) | Formulations pharmaceutiques | |
| HK1258699A1 (zh) | 包含酪氨酸蛋白激酶抑制劑的劑型組合物 | |
| EP3159340A4 (fr) | Nouvel inhibiteur de la tyrosine kinase de bruton | |
| MA46867A (fr) | Formulations pharmaceutiques | |
| ZA201906887B (en) | Bruton's tyrosine kinase inhibitors | |
| MA42303A (fr) | Formulations pharmaceutiques | |
| ZA201903694B (en) | Inhibitors of bruton's tyrosine kinase | |
| MA54716A (fr) | Réduction de la viscosité de formulations pharmaceutiques | |
| MA42510A (fr) | Formes et compositions d'inhibiteurs biaryles de la tyrosine kinase de bruton | |
| MA42509A (fr) | Formes d'adipate et compositions d'inhibiteurs de biaryle de la tyrosine kinase de bruton | |
| MA49837A (fr) | Compositions pharmaceutiques | |
| MA55015A (fr) | Formulations pharmaceutiques | |
| MA52629A (fr) | Agents inhibiteurs de la tyrosine kinase de bruton | |
| MA42546A (fr) | Combinaisons d'inhibiteur de la tyrosine kinase de bruton et leurs utilisations | |
| MA54095A (fr) | Formulations pharmaceutiques aqueuses | |
| MA46642A (fr) | Promédicaments d'inhibiteurs de la kallicréine | |
| MA49625A (fr) | Compositions pharmaceutiques |